Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRS, Temozolomide, and Erlotinib for NSCLC Brain Metastases
NCT00385398Phase 2Withdrawn
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Jul 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of erlotinib and temozolomide in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by University of Medicine and Dentistry of New Jersey. Planned start Jul 2008; status: withdrawn.
02
Drugs
erlotinibtemozolomide
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT00385398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00385398.